Biopharmaceutical company
Appears in 2 stories
Developing orexin agonists across sleep, ADHD and fatigue
Alkermes presented its orexin agonist as an ADHD treatment on September 21, the first time the new drug class has moved into a mainstream psychiatric market. The company calls the program a potential 'company changer.'
Updated Sep 21
Acquirer, now owns Avadel and LUMRYZ
Alkermes, a neuroscience-focused pharmaceutical company, completed its $2.37 billion acquisition of Avadel Pharmaceuticals on February 12, 2026, gaining immediate entry into the sleep medicine market. The deal adds LUMRYZ, the only once-nightly narcolepsy treatment, to Alkermes' portfolio alongside an emerging pipeline of orexin-based therapies.
Updated May 27
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
